Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Long-term risks associated with biologic response modifiers used in rheumatic diseases.

Anna K Imperato1, Stephen Smiles, Steven B Abramson

  • 1New York University School of Medicine/Hospital for Joint Diseases, 301 East 17th Street, Room 1410, New York, NY 10003, USA. impera01@med.nyu.edu

Current Opinion in Rheumatology
|April 23, 2004
PubMed
Summary

Tumor necrosis factor-alpha antagonists improve rheumatoid arthritis treatment but can cause rare, serious adverse events like infections and lymphoma. Ongoing surveillance is needed to assess their overall safety profile.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Implementing an accelerated three-year MD curriculum at NYU Grossman School of Medicine.

Medical teacher·2024
Same author

Interleukin-1 Receptor Antagonist Gene (IL1RN) Variants Modulate the Cytokine Release Syndrome and Mortality of COVID-19.

The Journal of infectious diseases·2024
Same author

Serum proteomic panel validated for prediction of knee osteoarthritis progression.

Osteoarthritis and cartilage open·2023
Same author

Pathological tissue formation and degradation biomarkers correlate with patient reported pain outcomes: an explorative study.

Osteoarthritis and cartilage open·2023
Same author

Interleukin-1 receptor antagonist gene ( <i>IL1RN</i> ) variants modulate the cytokine release syndrome and mortality of SARS-CoV-2.

medRxiv : the preprint server for health sciences·2023
Same author

Role of Intestinal Dysbiosis and Nutrition in Rheumatoid Arthritis.

Cells·2022

Area of Science:

  • Immunology
  • Rheumatology
  • Pharmacovigilance

Background:

  • Tumor necrosis factor-alpha (TNF-α) antagonists revolutionized rheumatoid arthritis (RA) treatment since 1998.
  • Increased global use has revealed rare adverse events not seen in initial clinical trials.

Purpose of the Study:

  • To review emerging adverse events associated with TNF-α antagonist therapy in RA.
  • To highlight the need for continued postmarketing surveillance.

Main Methods:

  • Review of postmarketing data and clinical trial findings.
  • Analysis of reported adverse events associated with TNF-α antagonists.

Main Results:

  • Serious infections, including atypical tuberculosis, are a significant concern.

Related Experiment Videos

  • Potential increased risk of lymphoma and development of lupus-like syndrome reported.
  • Rare cases of congestive heart failure and demyelinating syndromes linked to TNF-α antagonists.

    • Conclusions:

    • Postmarketing surveillance is crucial for understanding the true incidence of these adverse events.
    • Reassessment of the risk-benefit ratio of TNF-α antagonists may be necessary.